Presentation - Pharmacist Digest

STAT+: Cancer therapy’s new ‘gold rush’: bispecific antibodies that hit key combination of targets

STAT

JANUARY 22, 2025

” Experts told STAT there’s been a surge of interest for these compounds from biotech and pharma in the last few months, spurred on most by the presentation of promising clinical data from Summit Therapeutics.

Immunity

Immunity Immunization Compounding Drug Development

STAT+: How Pfizer used wearables to tap into the promise of an experimental drug

STAT

NOVEMBER 12, 2024

While the weight gain was significant, experts at the time said the study’s secondary endpoints, including patient-reported outcomes and physical activity measured by a wearable, presented a more nuanced portrait of how the treatment was influencing patients.

Opinion: Diagnostic tests for rare conditions present a mathematical conundrum

STAT

NOVEMBER 30, 2023

Worried about your health? You can now avail yourself of noninvasive diagnostics that claim to screen for rare birth defects, cancer-associated mutations, and even Alzheimer’s.

Labelling

STAT+: Genentech, a biotech with a storied past, confronts new turbulence in the present

STAT

SEPTEMBER 16, 2024

For decades, the biotech company Genentech has carved out a reputation in the industry as a scientist’s paradise, a place where researchers have developed new therapies in-house and published high-impact papers.

Experts say leaked messages present false link between gender-affirming care and cancer

STAT

MARCH 11, 2024

Hundreds of messages from an internal chat board for an international group of transgender health professionals were leaked in a think tank report last week and framed as revealing serious health risks associated with gender-affirming care, including cancer.

STAT+: Recursion presents mixed data on lead AI-derived drug candidate for potentially fatal brain condition

STAT

SEPTEMBER 3, 2024

Recursion Pharmaceuticals announced results of a clinical trial for its lead drug candidate Tuesday that, while a success on paper, likely won’t satisfy many investors closely watching the AI drug developer.

Drug Development

Opinion: Racism infects neuroscience’s past and present. What about its future?

STAT

DECEMBER 20, 2023

De-Shaine Murray is working at the cutting edge of neurotechnology. As a postdoctoral fellow at Yale, he is developing a device to monitor the brain following traumatic brain injury or stroke. He is also trying to fight the long legacy of racism in neuroscience.

STAT+: Cigna, Centene, Walgreens drop out of J.P. Morgan conference

STAT

JANUARY 13, 2025

Others that no longer appear on the final list of presenters: pharmacy chain Walgreens, medical device maker BD, insurer Oscar Health, physician practice management firm Agilon Health, medical device maker Inari Medical, biotech firm Applied Therapeutics, post-acute provider PACS, biotech firm IGM, and U.S. Morgan circulated on Dec.

STAT+: Jazz Pharmaceuticals to acquire Chimerix and its experimental brain cancer drug

STAT

MARCH 5, 2025

But in a clinical trial presented last year , 14 out of 50 patients with relapsed disease saw their tumors shrink. It responds poorly to chemotherapy and is usually driven by a mutation that can’t be drugged with traditional approaches. Median survival is generally cited as less than a year.

Chemotherapy

Chemotherapy Drug Development

STAT+: From Epic to FDA, all the leaders presenting at HHS’ invite-only AI in health care event

STAT

SEPTEMBER 17, 2024

Federal health officials wrestling with when and how to use artificial intelligence will on Wednesday host an invitation-only meeting of AI leaders across industry, academia, and government. Called “AI in Action: Transforming Health and Human Services,” the three-hour event is hosted by the federal health department.

Medical Schools

Medical Schools Hospitals

STAT+: How to eliminate biotech zombies: Buy them

STAT

FEBRUARY 27, 2025

Presently, Tang, via his hedge fund Tang Capital Partners and his privately held shell company, Concentra Biosciences, has a $3-per-share cash offer on the table to acquire and shut down Acelyrin, the distressed, cash-rich biotech that is seeking a second life as a merger partner with another troubled biotech.

Drug Development

Opinion: STAT+: Biotech investors: Stop expecting CRISPR science to make big leaps

STAT

APRIL 14, 2025

These studies often do not make a splash in the field and are almost never presented at major meetings, yet they provide guidance as to how best to harness the power of this technology. As scientists, we have taken on the drudgery of understanding the mechanism of action of CRISPR-directed gene editing and how to apply it.

Chemotherapy

Mayo Clinic’s partnership with dairy poses conflict of interest, critics say

STAT

MARCH 10, 2025

” Read the rest…

Mayo Clinic

Mayo Clinic Communication Hospitals

STAT+: At ASCO, AstraZeneca says its CAR-T therapy shrank solid liver tumors in early trial

STAT

JUNE 3, 2024

CHICAGO — A next-generation CAR-T therapy was able to substantially shrink tumors in patients with liver cancer in early clinical data presented Monday at the American Society of Clinical Oncology annual meeting.

Opioid cravings were reduced by anti-obesity drug in small study

STAT

FEBRUARY 17, 2024

DENVER — The GLP-1 medication liraglutide significantly reduced opioid cravings in a small analysis presented on Saturday. It is the first randomized controlled trial to test anti-obesity drugs against opioid addiction, which kills around 80,000 people in the U.S. Read the rest…

STAT+: Under-the-skin injection of Eisai’s Leqembi is as effective as IV infusion, new Alzheimer’s data show

STAT

OCTOBER 25, 2023

A version of the Alzheimer’s disease drug Leqembi that can be given with a simpler, under-the-skin injection is equally effective as the currently approved intravenous infusion, according to study results presented Wednesday by its maker, Eisai.

STAT+: Nvidia says a biological revolution is happening now. But is it?

STAT

JANUARY 9, 2024

The occasion: Nvidia, the chipmaker whose market capitalization has soared beyond $1 trillion because of its role in the revolutionary work occurring in artificial intelligence, was presenting at the J.P. ” When Kimberly Powell, Nvidia’s vice president of health care, finished her presentation, the room erupted in applause.

Palliative care for cancer patients is found to be as effective given virtually as in person

STAT

JUNE 2, 2024

CHICAGO — Comfort can be delivered to patients with advanced cancer virtually just as well as in person, according to a new study presented on Sunday at the American Society of Clinical Oncology annual meeting in Chicago.

Hospitals

STAT+: Could kidney transplant patients be spared a lifetime of immunosuppressants?

STAT

NOVEMBER 2, 2023

These treatments have side effects and toxicities that impact patients’ long-term health, and even survival, leading to a transplant failure rate of 30-50% at the 10-year mark. Continue to STAT+ to read the full story…

STAT+: ResMed CEO on how wearables, GLP-1s will impact sleep apnea device sales

STAT

OCTOBER 2, 2024

NEW YORK — The morning after presenting an upbeat outlook to analysts in a gilded hall in the New York Stock Exchange building, Mick Farrell, the CEO of ResMed, looked refreshed, despite a post-presentation cocktail reception. If the sleep tech magnate could have used more shuteye, he didn’t show it.

Dietary experts advise skipping guidelines on ultra-processed foods — for now

STAT

OCTOBER 21, 2024

Meeting Monday, the first of two days of presentations, they discussed research findings to inform a report to the Department of Health and Human Services and the Department of Agriculture. The results will be published in December.

STAT+: With an old approach but new energy, ADCs take center stage as promising cancer treatments

STAT

OCTOBER 24, 2023

MADRID — If you had to pinpoint one subject that stood out at this year’s European Society for Medical Oncology meeting , a massive conference with thousands of people from 140-some countries and 2,500 studies presented, it would be a burgeoning type of cancer treatment called antibody-drug conjugates.

Compounding

Compounding Drug Development

STAT+: Summit Therapeutics vs. Merck: Prepping for a big lung cancer study reveal

STAT

SEPTEMBER 5, 2024

Let’s set the table for Sunday’s presentation of the lung cancer immunotherapy trial known as HARMONi-2. Sunday’s HARMONi-2 presentation at the World Conference on Lung Cancer should provide the answers. Continue to STAT+ to read the full story…

Off-label treatment for alcohol use disorder is linked to slower liver decline, study suggests

STAT

MAY 22, 2024

The data, presented this week as an abstract at Digestive Disease Week in D.C., But a different medication, one frequently used off-label for the condition, could provide greater benefit to patients with alcohol-associated liver disease, a new study suggests.

Labelling

STAT+: Relay Therapeutics drug shows promise in early trial

STAT

SEPTEMBER 8, 2022

The results were released in an abstract at the annual meeting of the European Society of Molecular Oncology, where they will be presented in full on Sunday. Continue to STAT+ to read the full story…

STAT+: Merus drug, with immunotherapy, boosts tumor response in patients with head and neck cancer

STAT

MAY 28, 2024

But the Dutch drugmaker on Tuesday withheld additional information from the study related to the safety and durability of petosemtamab’s tumor responses, pending presentation at the annual meeting of the American Society of Clinical Oncology on June 3. Continue to STAT+ to read the full story…

Scientists document first-ever transmitted Alzheimer’s cases, tied to no-longer-used medical procedure

STAT

JANUARY 29, 2024

Part of it was the patients’ presentations: Some didn’t have the classic symptoms of the condition. LONDON — There was something odd about these Alzheimer’s cases. But it was also that the patients were in their 40s and 50s, even their 30s, far younger than people who normally develop the disease.

Documentation

The fight for control of methadone, addiction treatment’s ‘miracle molecule’

STAT

OCTOBER 20, 2023

A doctor, a patient advocate, and the most powerful figure in the methadone treatment industry presented competing visions for the future of American addiction medicine this week — a conversation that touched on stigma, patients’ rights, and a stark divide in health provider attitudes toward patients with addiction.

Listen: An ASCO preview & another Duchenne trial failure

STAT

MAY 30, 2024

Which presentations are worth catching at ASCO this weekend? This week on “The Readout LOUD,” we preview some of the research that will be presented at the American Society of Clinical Oncology conference in Chicago. What is exon-skipping? And how do you pronounce bronchiectasis?

Opinion: Functional neurological disorder is not an appropriate diagnosis for people with long Covid

STAT

JULY 15, 2024

Long Covid — the name adopted for cases of prolonged symptoms after an acute bout of Covid-19 — is an umbrella diagnosis covering a broad range of clinical presentations and abnormal biological processes.

STAT+: Eli Lilly’s obesity drug Zepbound improved liver scarring in mid-stage MASH study

STAT

JUNE 5, 2024

of patients on placebo who achieved this outcome, the results were statistically significant, according to an abstract of data that will be presented at the annual meeting of the European Association for the Study of the Liver. from the lowest to highest doses. When compared with the 29.7% Continue to STAT+ to read the full story…

Diabetes

Millions fewer people may need statins, a new study suggests. But guidelines have yet to agree

STAT

JUNE 10, 2024

That conversation may happen less often if changes in the risk model presented by the American Heart Association in November translate into new guidelines for prescribing statins.

SAEM Clinical Images Series: Purple Finger

ALiEM - Pharm Pearls

MARCH 18, 2024

A 30-year-old female with a past medical history of Crohn’s Disease presented to the ED for evaluation of an acutely bruised right 4th finger. She stated she was typing on a computer keyboard approximately 10 minutes prior to presentation and she noticed a sudden popping sensation at the base of her right ring finger.

STAT+: Kura Oncology highlights leukemia remission data as it enrolls larger trial

STAT

JUNE 11, 2023

FRANKFURT — A genetically targeted cancer drug from Kura Oncology has helped put more patients’ advanced leukemias into remission, according to updated results from an ongoing clinical trial presented Sunday.

Opinion: Pumping milk at JPM was a nightmare. It’s part of a bigger problem in the industry

STAT

JANUARY 11, 2024

Somehow, between back-to-back meetings and presentations, I’d have to bust out that abominable contraption and do my thing. But skipping a session ends up being even more painful. Naturally, I expected navigating the J.P. Morgan Healthcare Conference in San Francisco would be more complicated this year.

STAT+: In major test for prime editing, scientists successfully correct mutations in monkeys

STAT

OCTOBER 27, 2023

The results, presented at the European Society of Gene & Cell Therapy meeting in Brussels, are a major step for a technology that could transform treatment of numerous diseases. Prime Medicine said Friday it successfully used a new, ultra-versatile form of genetic surgery called prime editing to edit liver cells in monkeys.

STAT’s 2024 Diversity and Inclusion Report

STAT

OCTOBER 30, 2024

The STAT Diversity and Inclusion Committee presents STAT’s 2024 Diversity and Inclusion Report. Here, we share the self-reported gender and racial/ethnic demographics of our staff from STAT’s inception in 2015 through 2023, as well as our 2023 new hire demographics.

Male birth control research wins audience over at STAT Madness event

STAT

MARCH 22, 2024

That’s what attendees at the Breakthrough Summit East in New York had on their hands Thursday, as four participants presented their work in this year’s STAT Madness competition — an annual March Madness bracket-style battle to find the best innovation in science and medicine. A little madness. Read the rest…

STAT+: Pear’s shadow effect: Data from a Medicaid digital health experiment does the policy rounds

STAT

SEPTEMBER 19, 2023

In recent months, representatives of the Massachusetts state Medicaid program, MassHealth, have been presenting data suggesting reSET and reSET-O, Pear’s prescription apps that treat substance use disorder and opioid use disorder, saved the state money over a one-year period from 2021 to 2022.

STAT+: Gene therapies for deafness dredge up an old question: Do deaf people want a ‘cure’?

STAT

MAY 28, 2024

In October, he presented extraordinary data at a conference: His team had successfully enabled hearing in four congenitally deaf children using gene therapy. ’ said Shu, who is hearing and a professor at Fudan University in China. “That’s what really inspired me to think about developing a drug.”

Drug Development

Surge of respiratory disease in China triggers anxiety, but experts see likely explanation

STAT

NOVEMBER 23, 2023

But at present, a number of experts say the activity has a likely explanation: China’s population, especially its young children, probably developed significant immunological susceptibility to a range of respiratory pathogens during the years of China’s zero Covid policy.

New study sparks debate about whether H5N1 virus in cows is adapted to better infect humans

STAT

JULY 8, 2024

One of the things that determines what kind of animal a given flu virus can infect is the type of receptors present on the outside of tissues that virus comes in contact with. Across the globe, different influenza viruses are constantly circulating in many different kinds of animals.

RSV vaccines may be linked to small increased risk of developing Guillain-Barré syndrome, data suggest

STAT

FEBRUARY 29, 2024

At a meeting Thursday of the Advisory Committee on Immunization Practices, vaccine safety experts from the two agencies presented data that showed what appears to be an elevated rate of GBS, as the condition is called, among people who got the Pfizer vaccine, although there were also cases detected among people who got the GSK product.

Vaccines

Vaccines Immunity Immunization

Can MRIs ensure prostate cancer screening does more good than harm?

STAT

SEPTEMBER 25, 2024

Prostate cancer presents a tricky screening challenge. Catching it early could mean dodging a painful journey with advanced cancer.

STAT+: Cancer therapy’s new ‘gold rush’: bispecific antibodies that hit key combination of targets

STAT+: How Pfizer used wearables to tap into the promise of an experimental drug

Trending Sources

Opinion: Diagnostic tests for rare conditions present a mathematical conundrum

STAT+: Genentech, a biotech with a storied past, confronts new turbulence in the present

Experts say leaked messages present false link between gender-affirming care and cancer

STAT+: Recursion presents mixed data on lead AI-derived drug candidate for potentially fatal brain condition

Opinion: Racism infects neuroscience’s past and present. What about its future?

STAT+: Cigna, Centene, Walgreens drop out of J.P. Morgan conference

STAT+: Jazz Pharmaceuticals to acquire Chimerix and its experimental brain cancer drug

STAT+: From Epic to FDA, all the leaders presenting at HHS’ invite-only AI in health care event

STAT+: How to eliminate biotech zombies: Buy them

Opinion: STAT+: Biotech investors: Stop expecting CRISPR science to make big leaps

Mayo Clinic’s partnership with dairy poses conflict of interest, critics say

STAT+: At ASCO, AstraZeneca says its CAR-T therapy shrank solid liver tumors in early trial

Opioid cravings were reduced by anti-obesity drug in small study

STAT+: Under-the-skin injection of Eisai’s Leqembi is as effective as IV infusion, new Alzheimer’s data show

STAT+: Nvidia says a biological revolution is happening now. But is it?

Palliative care for cancer patients is found to be as effective given virtually as in person

STAT+: Could kidney transplant patients be spared a lifetime of immunosuppressants?

STAT+: ResMed CEO on how wearables, GLP-1s will impact sleep apnea device sales

Dietary experts advise skipping guidelines on ultra-processed foods — for now

STAT+: With an old approach but new energy, ADCs take center stage as promising cancer treatments

STAT+: Summit Therapeutics vs. Merck: Prepping for a big lung cancer study reveal

Off-label treatment for alcohol use disorder is linked to slower liver decline, study suggests

STAT+: Relay Therapeutics drug shows promise in early trial

STAT+: Merus drug, with immunotherapy, boosts tumor response in patients with head and neck cancer

Scientists document first-ever transmitted Alzheimer’s cases, tied to no-longer-used medical procedure

The fight for control of methadone, addiction treatment’s ‘miracle molecule’

Listen: An ASCO preview & another Duchenne trial failure

Opinion: Functional neurological disorder is not an appropriate diagnosis for people with long Covid

STAT+: Eli Lilly’s obesity drug Zepbound improved liver scarring in mid-stage MASH study

Millions fewer people may need statins, a new study suggests. But guidelines have yet to agree

SAEM Clinical Images Series: Purple Finger

STAT+: Kura Oncology highlights leukemia remission data as it enrolls larger trial

Opinion: Pumping milk at JPM was a nightmare. It’s part of a bigger problem in the industry

STAT+: In major test for prime editing, scientists successfully correct mutations in monkeys

STAT’s 2024 Diversity and Inclusion Report

Male birth control research wins audience over at STAT Madness event

STAT+: Pear’s shadow effect: Data from a Medicaid digital health experiment does the policy rounds

STAT+: Gene therapies for deafness dredge up an old question: Do deaf people want a ‘cure’?

Surge of respiratory disease in China triggers anxiety, but experts see likely explanation

New study sparks debate about whether H5N1 virus in cows is adapted to better infect humans

RSV vaccines may be linked to small increased risk of developing Guillain-Barré syndrome, data suggest

Can MRIs ensure prostate cancer screening does more good than harm?

Stay Connected